The 1 year trend is up both on the money flow and the volume for this stock, especially considering the reverse split and consequent dilution that occurred. Considering that reliable PR has it that people are recovering from a near state of blindness, we can expect to see considerable increases in share price, in spite of volatility which is endemic to the market. Also consider there are going to be an expanding range of therapeutic applications, for instance Dr. Atala in the NPR program mentioned heart and lung disease and other medical conditions. In fact every type of tissue in the body could benefit from this approach. Nothing goes up in a straight line, there is always programmed trading and speculators trying to knock the price down so they can pick up cheap shares and in fact it will be years before everyone with money to invest even finds out about this stock. Also you have scheduled sales of insider shares, why shouldn't they sell, they're going to keep getting options as the price increase so its just a form of income. It's no big deal when you already have a big salary and money invested.
I think I saw in one of the analyst's reports there is a mention that BLT may have to go to market again for more funds. So prescient investors may acting ahead of the trend. Having said that, this might be a real good time to buy more shares, because there could be some very some very important news generated from these trials.
That's a pretty big blunder on NPR saying that embryos are destroyed by this therapy. Also no mention there are many ways of obtaining stem cells other than embryonic stem cells. Would have been a good idea to mention at least something of Atala's credentials as well. "Anthony Atala, M.D. is the W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine, and Chair of the Department of Urology at Wake Forest School of Medicine in North Carolina. Regenerative medicine is "a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells."
I was reading an article that said the way Ebola infects cells is similar to the way HIV infects cells. Is it possible ddRNAi could be used as a therapy for Ebola as well as HIV?
Ok I see the article in the recent newsletter, but I just wonder why Calimmune didn't mention Benitec in the SFGATE article.
I see news in the linked article about re-engineering stem cells to eliminate the CCR5 receptor but I don't see anything about Benitec's ddRNAi technology. ACalimmune may be using something other than Benitec's patented technology.
There's always some stupid BS happening with this company. First the legacy of financial machinations, then Rabin conveniently not registering the sales of his shares, now an unexplained name change to Ocata, a stupid name if I ever heard one. The preliminary proxy states " We are changing our name in order to create a new corporate brand for the Company and emphasize the Company’s focus on developing therapeutics which may have use as treatment for diseases of the eye". What about the myriad other therapies that they are working on. Are the going to create this company just to work specifically on eye related therapies and divide out all the other possible uses for stem cell therapies into other companies? Something fishy is going on here and it demands explanation.
I have come to know and love the name Advanced Cell. What possible rationale could there be for changing the name to Ocata. This is a bizarre turn of events and it's unexplained stuff like this that makes me think something continues to be out of joint at this company. Hope someone has a reasonable explanation for this or else its thumbs down.
Went all the way to $47.25 before dropping back down to around $10 again. Must be the result of institutional buying. If I was an institutional buyer I would be jumping in now because Applied Cell Technology is the Microsoft of Stem Cells. Their therapies will regenerate every part of the body over time, the growth story here is huge, I believe they will even use stem cells to cure cancer. Now I'm going to buy more shares.
Is about where it was 2 years ago in spite of the issuance of additional shares. The RS and up-list should increase the demand for shares and if the RS is made from a position of strength (good news) then the share price should increase. If the RS was done from a position of weakness with bad clinical results or dire financial need then the price would fall.
Georgejji, I have couple questions to you. One of the questions presented by a reviewer at a board that approved the tests for TT-034 had pose a question about the buildup of some of the short hairpins in the targeted cells. In other words what if there is an uneven distribution of the short hairpins in the targeted or what if the short hairpins produced by the DNA constructs in the targeted cells exceed the virus rna's. Could this result in some form of toxicity or what is the ultimate breakdown and disposal process that occurs to the DNA construct in the nucleus and/or any surplus shRNA in the targeted cells.
Don't worry so much. There will be a reverse split 130/1 along with announcement of clinical trial data, possible publication of article in med journal, up-list to NASDAQ, possible announcement of joint ventures with bio partners, and announcement of further clinical developments. Everything is going to be ok.
Christianity is a mind game imposed by the Romans to cement their empire. The Mideast and Africa became Muslim (another mind game) quickly after the Roman Empire fell apart in those areas because Arabs invaded and took over. The Romans were able to defend the remnants of their hegemony in Europe so Christianity remained pre-dominant there and the Illuminati continued the pattern of using their brainwashed pawns as cannon fodder to impose their financial interests and control the population.